EDGAR·FLOW

Atea Pharmaceuticals, Inc. — Form 8-K

Filed November 9, 2026 · analyzed by the 8-K Agent
8-K ▲ Likely positive significance 76/100
What the filing says
Atea Pharmaceuticals entered into a Loan and Security Agreement dated November 6, 2026, with Hercules Capital, Inc. as agent and lender, providing access to up to $200,000,000 in term loans across five tranches. The loan is secured by substantially all of Atea's assets, including intellectual property related to its BEM/RZR product candidate. Proceeds may be used for acquisitions, working capital, and general corporate purposes, with specific covenants tied to cash maintenance, product revenue milestones, and regulatory compliance.
Why this rating

$200M facility is 76% of company's $262.6M market cap—transformational for funding runway and balance sheet, though terms include restrictive covenants and significant fees.

Tradability signal
NO TRADE

No trade: positive news with no measurable pre-read move — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.44% over 4 hrs, n=402). (Filing arrived outside market hours — evaluated at the next open with a live quote.)

Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.

Price action (we called it positive)
at our read · unknown
$4.34
+10 min · unknown
$4.33 ▼ 0.35%
+30 min · unknown
$4.32 ▼ 0.58%
+1 hr · unknown
$4.41 ▲ 1.61%
+4 hrs · unknown
$4.41 ▲ 1.61%

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ AVIR · stock on Yahoo Finance ↗

See more from November 9, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.